Evaluating personalized medication based on genetic testing for psychiatric disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of pharmacogenetics-informed pharmacotherapy compared to standard dosing in patients with mood, anxiety, or psychotic disorders. Over 24 weeks, participants will receive personalized medication advice based on their genetic profiles, which may predict their response to treatment and side effects. The study is designed to be patient- and rater-blinded, ensuring unbiased results. It aims to demonstrate the clinical benefits of integrating pharmacogenetic testing into psychiatric care, potentially improving treatment outcomes for a diverse patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Suffer from a depressive episode (major depressive disorder and bipolar disorder (currently depressive episode)) (as assessed by the MINI International Neuropsychiatric Interview (M.I.N.I.) in agreement with Diagnostic and Statistical Manual (DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Depression Scale (SIGH-D) with a score of 14 or higher) and/or suffer from an anxiety disorder (panic disorder, generalised anxiety disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Structured Interview Guide for the Hamilton Anxiety Scale (SIGH- A) with a score of 18 or higher) and/or suffer from a psychotic disorder (schizophrenia and schizoaffective disorder) (as assessed by the M.I.N.I. in agreement with DSM-5 criteria) of at least moderate severity (assessed using the Positive and Negative Symptom Scale (PANSS) with a score of 75 or higher).
2. Have had an inadequate response to at least 1 psychotropic treatment during their life-time. Inadequate response is defined as insufficient efficacy of a psychotropic treatment when dosed high enough and maintained long enough, or discontinuation of a psychotropic treatment due to AEs or intolerability.
3. Are about to switch (or have switched within the last 2 weeks prior to first contact with an investigator) to sertraline or escitalopram (for patients with mood or anxiety disorders), or to aripiprazole or risperidone (for patients with psychotic disorders) due to an inadequate response to or intolerance of the current/ previous medication.
4. Currently receiving inpatient or outpatient psychiatric treatment.
5. Be able to understand the requirements of the study and provide written informed consent to participate in this study; a signed and dated informed consent form (ICF) will be obtained from each patient before participation in the study.
6. To give written consent to the use and disclosure of clinical data from their medical records for the purpose of this study.
7. Age between ≥16 and \<70 years.
8. Ownership of a mobile phone (Android or iOS operation system) for passive monitoring.

Exclusion Criteria:

1. Patients with a history of prior pharmacogenomic testing
2. Patients with no prior use of psychotropic medication (medication-naïve patients)
3. Severe somatic comorbidities as reported in the subject's medical history or based on clinical chemistry/electrocardiography (ECG) results up to six months ago. If any of these comorbidities is detected on the basis of physical examination and/or clinical chemistry and/or ECG at the screening visit, participation is not possible.

   * Liver disease defined as follows: Alanine-Aminotransferase (ALAT) \>70u/L
   * Renal disease: Estimated glomerular filtration rate (eGFR) \< 60ml/min/1.73m2
   * Diabetes: Blood glucose \> 11.1 mmol/L or twice a fasting glucose \> 7.0 mmol/L
   * Cardiac disease: prolonged QT-interval.
4. Alcohol and/or substance abuse and/or dependence (except nicotine)
5. Polypharmacy defined as the routine use of five or more medications including over- the-counter, prescription and/or traditional and complementary medicines used by a patient (WHO 2019).
6. Inability to use the mobile phone application
7. Pregnant or breastfeeding women

Where it's running

• University Hospital Bonn, Department of Psychiatry and Psychotherapy
  Bonn, Germany Recruiting
• Ludwig-Maximilian University, University Hospital, Institute of Psychiatric Phenomics and Genomics (IPPG)
  München, Germany Recruiting
• Parnassia Psychiatric Institute, Department of Psychiatry
  Amsterdam, Netherlands Recruiting
• Maastricht University, Department of Psychiatry and Neuropsychology
  Maastricht, Netherlands Recruiting
• Babeş-Bolyai University, Department of Clinical Psychology and Psychotherapy
  Cluj-Napoca, Romania Recruiting
• University of Belgrade, Faculty of Pharmacy
  Belgrade, Serbia Recruiting

Study contacts

• Principal investigator: Roos van Westrhenen, Professor (PhD&MD) — Parnassia Psychiatric Institute (Amsterdam, Parnassia Groep)
• Study coordinator: Roos van Westrhenen, Professor (MD&PhD)
• Email: r.vanwestrhenen@psyq.nl
• Phone: +31 883583398

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventive behavioral intervention for young adults with psychotic experiences

  This study is testing if a new Resilience Training program can help college freshmen and sophomores who are at risk for serious mental illnesses feel better and prevent issues like psychosis, mood swings, and anxiety.

  Recruiting Massachusetts General Hospital · Charlestown, Massachusetts · NCT06929442

• Understanding sensory profiles of patients using a calming room

  This study looks at how patients in a psychiatric hospital respond to different senses before and after using a calming room to see if their sensory experiences affect their mental health.

  Recruiting Centre Hospitalier Esquirol · Limoges, New Aquitaine · NCT06839950

• Cognitive Behavioural Therapy for youth with mood and anxiety disorders

  This study is testing a new type of Cognitive Behavioural Therapy called CBT-MyOWL for young people aged 14-19 with mood and anxiety disorders to see if it helps them stick with treatment and feel better compared to standard therapy.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT06532500

• Developing a group treatment to help teens at risk for serious mental illness

  This study is testing a new group program to help high school students with mild signs of depression or anxiety build resilience and prevent serious mental health issues.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT05962879

• Combining neurostimulation with emotion regulation training for emotional issues

  This study is testing if combining brain stimulation with training on how to manage emotions can help people with emotional issues feel better.

  Recruiting Duke University · Durham, North Carolina · NCT05712057

• Using RxWell to Reduce Opioid Use After Knee or Hip Surgery

  This study is testing whether a digital tool called RxWell can help people with mood disorders who are having knee or hip surgery reduce their opioid use and improve their mental health after the operation.

  Recruiting at 3 sites University of Pittsburgh · Monroeville, Pennsylvania and 2 other locations · NCT05658796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.